Study summary · research use only
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review describes the structure, mechanism of action, and therapeutic potential of Elamipretide (SS-31, MTP-131, Bendavia), a mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. The authors report that Elamipretide stabilizes mitochondrial cristae structure, reduces oxidative stress, and enhances ATP production, and summarize preclinical studies in models of heart failure, neurodegeneration, ischemia-reperfusion injury, metabolic syndromes, and muscle atrophy and weakness. Clinical trials referenced include PROGRESS-HF, TAZPOWER, MMPOWER-3, and ReCLAIM. The review states that further research may extend Elamipretide's application to other diseases involving mitochondrial dysfunction and examine its long-term use.
Abstract
Mitochondria serve an essential metabolic and energetic role in cellular activity, and their dysfunction has been implicated in a wide range of disorders, including cardiovascular conditions, neurodegenerative disorders, and metabolic syndromes. Mitochondria-targeted therapies, such as Elamipretide (SS-31, MTP-131, Bendavia), have consequently emerged as a topic of scientific and clinical interest. Elamipretide has a unique structure allowing for uptake in a variety of cell types and highly selective mitochondrial targeting. This mitochondria-targeting tetrapeptide selectively binds cardiolipin (CL), a lipid found in the inner mitochondrial membrane, thus stabilizing mitochondrial cristae structure, reducing oxidative stress, and enhancing adenosine triphosphate (ATP) production. Preclinical studies have demonstrated the protective and restorative efficacy of Elamipretide in models of heart failure, neurodegeneration, ischemia-reperfusion injury, metabolic syndromes, and muscle atrophy and weakness. Clinical trials such as PROGRESS-HF, TAZPOWER, MMPOWER-3, and ReCLAIM elaborate on preclinical findings and highlight the significant therapeutic potential of Elamipretide. Further research may expand its application to other diseases involving mitochondrial dysfunction as well as investigate long-term efficacy and safety of the drug. The following review synthesizes current knowledge of the structure, mechanisms of action, and the promising therapeutic role of Elamipretide in stabilizing mitochondrial fitness, improving mitochondrial bioenergetics, and minimizing oxidative stress.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.